Liver Fibrosis and Five Year HCC Survival with TACE Using Small Doses

Hepatocellular carcinoma (HCC) have a higher incidence in malignant tumors. It has replaced carcinoma of stomach to be the second highest incidence in China (Yan, 2002). Trancatheter arterial chemoembolization (TACE) is the chief therapeutic method to middle-late period PHC patients, TACE can promote tumor necrosis by directly kill tumor cells and block tumor’s blood supply, so as to achieve the therapeutic purposes.However ,different doses different chemotherapeutics and lipiodol in TACE will damage normal liver parenchyma, induce even aggravate liver fibrosis.But because potential chronic liver injury can’t be found by routine examination,which cause clinical can’t understand it sufficiently for a long time. Over several years, the phenomenon like progressive chronic liver injury , aggravating liver cirrhosis after more than once TACE graduatelly become a hot problem that some clinical studies pay close attention to (Zhu et al., 2000; Feng et al., 2002; Lu et al., 2004). Scholars both domestic and overseas found that , one significant reason that cause liver fibrosis was huge doses chemotherapeutics in TACE (Chung et al., 1996; Feng et al., 2002; Lu et al., 2004). Researches demonstrate that normal liver tissue iodized oil embolization can cause or worsen liver fibrosis, so that they advocated superselective TACE (Xiao et al., 1997). But some research indicated that there was still certain concentration drugs